Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral vinorelbine + cisplatin with concurrent radiotherapy ± consolidation in stage III NSCLC
2004-005135-26Phase 3Terminated
- Sponsor
- Pierre Fabre Laboratories
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of vinorelbine and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pierre Fabre Laboratories. Primary endpoint: Progression-free survival. Started Mar 2005; status: terminated.
02
Drugs
vinorelbinecisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-005135-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005135-26.